Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 24;30(5):4437-4482.
doi: 10.3390/curroncol30050338.

Mesenchymal Tumors of the Breast: Fibroblastic/Myofibroblastic Lesions and Other Lesions

Riordan Azam  1 , Miralem Mrkonjic  2   3 , Abha Gupta  4   5 , Rebecca Gladdy  3   6 , Andrea M Covelli  3   6
Affiliations
Review

Mesenchymal Tumors of the Breast: Fibroblastic/Myofibroblastic Lesions and Other Lesions

Riordan Azam et al. Curr Oncol. .

Abstract

Mesenchymal breast tumors are a rare and diverse group of tumors that present some of the most challenging cases for multidisciplinary breast cancer teams. As a result of overlapping morphologies and a lack of large-scale studies on these tumors, practices are often heterogeneous and slow to evolve. Herein, we present a non-systematic review that focuses on progress, or lack thereof, in the field of mesenchymal breast tumors. We focus on tumors originating from fibroblastic/myofibroblastic cells and tumors originating from less common cellular origins (smooth muscle, neural tissue, adipose tissue, vascular tissue, etc.).

Keywords: breast tumors; fibroblastic; mesenchymal tumors; myofibroblastic; spindle cell tumors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mesenchymal Tumors of the Breast, Fibroblastic/Myofibroblastic Origin, and Tumors of “Other” Cellular Origin.
Figure 2
Figure 2
Nodular Fasciitis, low-power field, well-encapsulated mass.
Figure 3
Figure 3
Nodular fasciitis, high power field (hpf), fibroblasts, and myofibroblasts with occasional lymphocytes and extravasated RBCs.
Figure 4
Figure 4
Myofibroblastoma, low power field, well-encapsulated mass.
Figure 5
Figure 5
Myofibroblastoma, hpf, (a) haphazard fascicles with variably hyalinized collagen (b) storiform architecture.
Figure 6
Figure 6
Fibromatosis, hpf, peripheral lymphoid aggregates, and fat entrapment.
Figure 7
Figure 7
Fibromatosis, IHC for beta-catenin showing nuclear and cytoplasmic staining.
Figure 8
Figure 8
Inflammatory Myofibroblastic Tumor, myofibroblasts, and inflammatory cells.
Figure 9
Figure 9
Dermatofibrosarcoma protuberans, honeycombing of fat.
Figure 10
Figure 10
Dermatofibrosarcoma protuberans, IHC staining positive for CD34.
Figure 11
Figure 11
Neurofibroma, (a) with overlying skin; (b) on excision with comma-shaped nuclei and “shredded-carrot-like” stroma.
Figure 12
Figure 12
Fanburg-Smith Criteria for Differentiating Malignant and Benign Granular Cell Tumors.
Figure 13
Figure 13
Lipoma, normal adipocytes with small nuclei and interspersed fibrous septae.
Figure 14
Figure 14
Angiolipoma, mature adipocytes with interspersed, uneven distribution of blood vessels in lobulated collections.
Figure 15
Figure 15
Hemangioma, area of dilated capillary-like vascular spaces with bland endothelium.
Figure 16
Figure 16
Atypical Vascular Lesion, Anastomosed lymphatic or capillary vessels, no mitoses or MYC rearrangements.
Figure 17
Figure 17
Pseudo-Angiomatous Stromal Hyperplasia, pseudo-vascular slit-like spaces without red blood cells.
See this image and copyright information in PMC

References

    1. Boldt C. MD Anderson and the Rare Cancer Research Foundation Launch Collaboration to Accelerate the Development of Treatments for Rare Cancers. MD Anderson Newsroom. 2021. [(accessed on 18 February 2023)]. Available online: https://www.mdanderson.org/newsroom/md-anderson-rare-cancer-research-fou....
    1. Konwaler B.E., Keasbey L., Kaplan L. Subcutaneous Pseudosarcomatous Fibromatosis (Fasciitis) Am. J. Clin. Pathol. 1955;25:241–252. doi: 10.1093/ajcp/25.3.241. - DOI - PubMed
    1. Hara H., Fujita I., Fujimoto T., Hanioka K., Akisue T., Kurosaka M. Nodular Fasciitis of the Hand in a Young Athlete. A Case Report. Upsala J. Med. Sci. 2010;115:291–296. doi: 10.3109/03009734.2010.500746. - DOI - PMC - PubMed
    1. Zhao M., Yin X., Wen Y., Ru G., Meng X. Nodular Fasciitis of the Breast: Report of Two Cases Illustrating the Diagnostic Implications for USP6 Gene Rearrangement and Brief Review of the Literature. Exp. Mol. Pathol. 2021;123:104690. doi: 10.1016/j.yexmp.2021.104690. - DOI - PubMed
    1. Cloutier J.M., Kunder C.A., Charville G.W., Hosfield E.M., García J.J., Brown R.A., Troxell M.L., Allison K.H., Bean G.R. Nodular Fasciitis of the Breast: Clinicopathologic and Molecular Characterization with Identification of Novel USP6 Fusion Partners. Mod. Pathol. 2021;34:1865–1875. doi: 10.1038/s41379-021-00844-4. - DOI - PubMed